Featured Image

Top Health Care Stocks

JNJ +1.29%

PFE +1.11%

ABT +0.72%

MRK +0.35%

AMGN +0.73%

Health care stocks were moderately higher this afternoon, including a more than 0.4% gain for shares of health care companies in the S&P 500 while the Nasdaq Biotechnology index was climbing about 1.0%. The NYSE Health Care Index climbed nearly 0.4%.

Among health care stocks moving on news:

(-) Cesca Therapeutics ( KOOL ) dropped over 11% on Tuesday after the cell-based therapeutics company reported a FY18 net loss of $2.16 per share, representing a nearly four-fold increase over its $0.55 per share net loss during the prior-year period. Revenue fell 24.3% to $9.67 million during the 12 months ended Dec. 31 from $12.77 million in FY17. Analyst estimates were not available for comparison.

In other sector news:

(+) aTyr Pharma ( LIFE ) was climbing about 5% this afternoon after the immuno-oncology company late Monday nearly halved its Q4 net loss compared with the year-ago period, reporting a $0.21 per share net loss for the three months ended Dec. 31 versus a $0.39 per share loss during the final quarter in 2017. aTyr had no revenue during either reporting period.

(-) Natera ( NTRA ) was narrowly lower this afternoon. The genetic testing company Tuesday said it was partnering with privately held AMAL Therapeutics to assess the safety, tolerability and preliminary efficacy of a combination of its ATP128 cancer vaccine and a PD1 blockade in patients with stage IV colorectal cancer. Natera also was sued late Monday in a federal court in Delaware, accused of infringing on two Stanford University patents licensed by CareDX (CDNX) with its cell-free DNA test for potential rejection in transplant patients.

(-) OpGen ( OPGN ) plunged 36% after the precision medicines company priced a $5.4 million public offering of 9 million shares of its common stock at $0.60 cents apiece, representing a 32% discount from Monday's closing price.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.


Related Articles